| Report ID | 274981 |
| Drug Identification Number | 02499894 |
| Brand name | NAT-OSELTAMIVIR |
| Common or Proper name | OSELTAMIVIR |
| Company Name | NATCO PHARMA (CANADA) INC |
| Market Status | MARKETED |
| Active Ingredient(s) | OSELTAMIVIR |
| Strength(s) | 6MG |
| Dosage form(s) | POWDER FOR SUSPENSION |
| Route of administration | ORAL |
| Packaging size | 1 BOTTLE |
| ATC code | J05AH |
| ATC description | DIRECT ACTING ANTIVIRALS |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | |
| Actual start date | 2025-12-31 |
| Estimated end date | Unknown |
| Actual end date | |
| Shortage status | Actual shortage |
| Updated date | 2026-01-01 |
| Company comments | Due to increase in demand there might be a shortage for NAT-Oseltamivir Suspension. NAT-OSELTAMIVIR (oseltamivir phosphate) Capsules 75 mg remain available for compounding a suspension if NAT-Oseltamivir Oral Suspension is not available. Refer to the product monograph for compounding instructions. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 2000 ARGENTIA ROAD, PLAZA 1, SUITE 200 MISSISSAUGA, ONTARIO CANADA L5N 1P7 |
| Company contact information |
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v7 | 2026-01-01 | English | Compare |
| v6 | 2025-12-31 | French | Compare |
| v5 | 2025-12-31 | English | Compare |
| v4 | 2025-12-31 | English | Compare |
| v3 | 2025-12-24 | French | Compare |
| v2 | 2025-12-24 | English | Compare |
| v1 | 2025-12-24 | English | Compare |
Showing 1 to 7 of 7